Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication

Figures & data

Table 1 Basic characteristics

Characteristics	n	Gender	n	Age, years (range)
Newly diagnosed	36	Male	30
Relapsed	6			35 (14–70)
Complete remission	20	Female	32
Healthy donors	30	Male	14	34 (18–48)
		Female	16

Table 2 PCR conditions and primers

Gene	Primer sequences forward and reverse	PCR cycling conditions	Product length (bp)
SHP-1	F: 5′-GGGCAGGCAGAGACGCT-3′	94°C/45″ 56°C/45″	238
	R: 5′-CTTCTTGAAATGCTCCACCA-3′	72°C/60″
SOCS6	F: 5′-TCTCACCATTGCTACTCCA-3′	94°C/45″ 55°C/45″	466
	R: 5′-GAGTCCCTGATTGAATGCTC-3′	72°C/60″
β-Actin	F: 5′-TCATCACCATTGGCAATGAG-3′	94°C/45″ 55°C/45″	150
	R: 5′-CACTGTGTTGGCGTACAGGT-3′	72°C/60″

Abbreviations: PCR, polymerase chain reaction; SHP-1, Src homology region 2 domain-containing phosphatase-1; SOCS6, suppressor of cytokine signaling 6; F, forward; R, reverse.

Figure 1 mRNA expression of SHP-1 and SOCS6 in AL patients. (A) mRNA expression of SHP-1 in AL patients; (B) mRNA expression of SOCS6 in AL patients.

Notes: *Versus healthy donor, P<0.05; ^#versus newly diagnosed, P<0.05; ^∆versus CR, P<0.05.
Abbreviations: AL, acute leukemia; CR, complete remission; mRNA, messenger RNA; SHP-1, Src homology region 2 domain-containing phosphatase-1; SOCS6, suppressor of cytokine signaling 6.

Table 3 Effect of SHP-1 and SOCS6 mRNA expression on patient outcomes

Outcome	SHP-1 mRNA expression		χ^2	P-value	SOCS6 mRNA expression		χ^2	P-value
	Detectable	Undetectable			Detectable	Undetectable
Chemotherapy-induced remission	100% (9/9)	48% (16/33)	5.79	<0.05	66% (25/38)	0% (0/4)	4.06	<0.05
Invasive fungal infection	11% (1/9)	97% (32/33)	26.07	<0.01	88% (29/38)	100% (4/4)	0.21	>0.05

Abbreviations: mRNA, messenger RNA; SHP-1, Src homology region 2 domain-containing phosphatase-1; SOCS6, suppressor of cytokine signaling 6.